4D Molecular Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Cash & Equivalents	249.11	52.35	153	276.73	49.65	91.76
Short-Term Investments	39.12	161.2	94.78	0	0	0
Cash & Cash Equivalents	288.23	213.55	247.78	276.73	49.65	91.76
Cash Growth	34.97%	-13.81%	-10.46%	457.33%	-45.89%	-
Receivables	0	0	0.05	1.49	0.98	1.12
Other Current Assets	8.36	6.96	8.46	4.44	1.88	1.18
Total Current Assets	296.59	220.51	256.28	282.66	52.51	94.07
Property, Plant & Equipment	31.67	35.35	28.95	5.07	5.05	2.47
Long-Term Investments	10.95	4.91	67.65	0	0	0
Other Long-Term Assets	0.68	1.08	0.6	0.6	0.68	0.43
Total Long-Term Assets	43.3	41.34	97.21	5.68	5.73	2.9
Total Assets	339.89	261.85	353.49	288.33	58.23	96.97
Accounts Payable	3.52	3.32	4.76	1.79	1.74	0.95
Deferred Revenue	1.25	1.96	5.09	19.81	19.47	17.98
Current Debt	3.15	2.66	1.23	0	0	0
Other Current Liabilities	11.04	7.79	5.25	-4.86	-8.26	-10.88
Total Current Liabilities	18.95	15.73	16.34	16.74	12.96	8.05
Long-Term Debt	11.52	13.47	15.22	0	0	0
Other Long-Term Liabilities	1.59	1.31	2.83	15.2	15.27	13.52
Total Long-Term Liabilities	13.11	14.78	18.04	15.2	15.27	13.52
Total Liabilities	32.06	30.51	34.38	31.94	28.22	21.58
Total Debt	14.67	16.12	16.45	0	0	0
Debt Growth	-9.01%	-1.97%	-	-	-	-
Retained Earnings	-415.33	-314.49	-207	-135.68	-79.03	-30.03
Comprehensive Income	0.02	-1.2	-0.42	0	0	0
Shareholders' Equity	307.83	231.34	319.11	256.39	-72.97	-27.59
Net Cash / Debt	273.56	197.43	231.33	276.73	49.65	91.76
Net Cash / Debt Growth	38.56%	-14.65%	-16.41%	457.33%	-45.89%	-
Net Cash Per Share	6.99	6.10	8.34	43.03	9.66	18.17
Working Capital	277.64	204.78	239.94	265.91	39.55	86.01
Book Value Per Share	7.87	7.15	11.51	39.87	-14.19	-5.46

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).